# Evaluating the Effect of Standard-of-care Erythropoiesis-stimulating Agents on Forearm Blood Flow in Nondialysis-dependent Subjects With Anaemia Associated With Chronic Kidney Disease.

> **NCT02987465** · — · COMPLETED · sponsor: **Cambridge University Hospitals NHS Foundation Trust** · enrollment: 29 (actual)

## Conditions studied

- Cardiovascular Diseases
- Chronic Kidney Disease

## Interventions

- **DRUG:** Darbepoetin Alfa
- **DRUG:** Acetylcholine
- **DRUG:** Noradrenaline
- **DRUG:** BQ 123

## Key facts

- **NCT ID:** NCT02987465
- **Lead sponsor:** Cambridge University Hospitals NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-20
- **Primary completion:** 2018-05-21
- **Final completion:** 2018-05-21
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2024-02-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02987465

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02987465, "Evaluating the Effect of Standard-of-care Erythropoiesis-stimulating Agents on Forearm Blood Flow in Nondialysis-dependent Subjects With Anaemia Associated With Chronic Kidney Disease.". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02987465. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*